Germany · Delayed Price · Currency is EUR RemeGen Company Description
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers.
It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors.
The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
| Country | China |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 2,999 |
| CEO | Jianmin Fang |
Contact Details
Address: 58 Middle Beijing Road Yantai China | |
| Phone | 86 53 5611 3511 |
| Website | remegen.com |
Stock Details
| Ticker Symbol | REG |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jianmin Fang | Chief Executive Officer |
| Shaojing Tong | Chief Financial Officer |
| Kaisheng Huang | Chief Operating Officer |